Details of Disease

General Information of Disease (ID: DIS6SXQD)

• Disease Name: Pneumococcal infection
• Synonyms: pneumoniae infection, Streptococcus; infection, pneumococcal; infections, pneumococcal; infection, Streptococcus pneumoniae; Streptococcus pneumoniae infection; pneumoniae infections, Streptococcus; infections, Streptococcus pneumoniae; Streptococcus pneumoniae infections; Streptococcus pneumoniae disease or disorder; Streptococcus pneumoniae infectious disease; pneumococcal infection; Streptococcus pneumoniae caused disease or disorder
• Disease Class: CA00-CA40: Pneumococcal infection
• Definition: Infections with bacteria of the species streptococcus pneumoniae.
• Disease Hierarchy:
  DIS04U9T: Streptococcus infection
  DISEM33Q: Infectious disease
  DIS6SXQD: Pneumococcal infection
• ICD Code: ICD-11: ICD-11: CA00-CA40
• Disease Identifiers:
  MONDO ID: MONDO_0005114
  MESH ID: D011008
  UMLS CUI: C0032269
  MedGen ID: 18528
  SNOMED CT ID: 16814004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Fusidic Acid	DMWVCF3	Approved	Small molecular drug	[1]
Lincomycin	DMVTHER	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 16 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PF-06482077	DMKH7QM	Phase 3	NA	[3]
Polyvalent pneumococcal conjugate vaccine	DMJ3QMJ	Phase 3	Vaccine	[4]
V114	DMDEYLO	Phase 3	Vaccine	[5]
V116	DM6X509	Phase 3	Vaccine	[6]
ASP3772	DMRTXCH	Phase 2	Vaccine	[7]
GSK-2189242A	DMOQFAA	Phase 2	NA	[8]
GSK2254233A	DMSHKAA	Phase 2	NA	[9]
GSK2830930A	DM8RC7M	Phase 2	NA	[10]
GSK5101955A	DM028OF	Phase 2	Vaccine	[11]
GSK5101956A	DM8RAW4	Phase 2	Vaccine	[11]
HibTITER	DMO10JI	Phase 2	Vaccine	[12]
KP-1461	DMG02ET	Phase 2	Small molecular drug	[13]
Next Gen PCV	DMEOGGI	Phase 2	Vaccine	[14]
PF-06842433	DMFEXXY	Phase 2	Vaccine	[15]
SP0202	DMV7RMT	Phase 2	Vaccine	[16]
TVI-Brain-1 cancer vaccine	DM776EU	Phase 2	NA	[17]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
IL31RA	TT9HPX0	Limited	Biomarker	[18]
IRAK4	TTILUKB	Limited	Biomarker	[19]
TIRAP	TTKU0LS	Limited	Biomarker	[20]
PTAFR	TTQL5VC	moderate	Biomarker	[21]
MBL2	TTMQDZ5	Strong	Biomarker	[22]

This Disease Is Related to 10 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
COLEC11	OT4GC46Y	Limited	Biomarker	[23]
IL22RA1	OTGVKLBR	Limited	Biomarker	[24]
ITIH4	OT460OO1	Limited	Biomarker	[25]
SARS1	OTFKXQ1O	Limited	Biomarker	[26]
SARS2	OTU4T99W	Limited	Biomarker	[26]
SBNO1	OTNX3RL0	Limited	Altered Expression	[27]
TONSL	OTBWODM9	Limited	Genetic Variation	[28]
SPDYA	OTYKC1AJ	moderate	Biomarker	[29]
EEF1A1	OT00THXS	Strong	Biomarker	[30]
NFKBIZ	OTU728KS	Strong	Genetic Variation	[31]

References

• [1] Epidemiology of penicillin resistant pneumococci in Iceland. Microb Drug Resist. 1995 Summer;1(2):121-5.
• [2] Lincomycin FDA Label
• [3] Clinical pipeline report, company report or official report of Pfizer.
• [4] ClinicalTrials.gov (NCT00496093) Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011). U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT04384107) Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033). U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT05425732) A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-na?ve Adults. U.S.National Institutes of Health.
• [7] ClinicalTrials.gov (NCT03803202) A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT01262872) Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants. U.S. National Institutes of Health.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029791)
• [10] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011380)
• [13] ClinicalTrials.gov (NCT00504452) Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients. U.S. National Institutes of Health.
• [14] Clinical pipeline report, company report or official report of Sanofi.
• [15] Clinical pipeline report, company report or official report of Pfizer.
• [16] ClinicalTrials.gov (NCT04583618) Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Aged 50 to 84 Years. U.S.National Institutes of Health.
• [17] ClinicalTrials.gov (NCT01290692) Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma. U.S. National Institutes of Health.
• [18] Lactobacillus casei CRL 431 improves endothelial and platelet functionality in a pneumococcal infection model.Benef Microbes. 2019 May 28;10(5):533-541. doi: 10.3920/BM2018.0099. Epub 2019 Apr 9.
• [19] Complete dependence on IRAK4 kinase activity in TLR2, but not TLR4, signaling pathways underlies decreased cytokine production and increased susceptibility to Streptococcus pneumoniae infection in IRAK4 kinase-inactive mice.J Immunol. 2013 Jan 1;190(1):307-16. doi: 10.4049/jimmunol.1201644. Epub 2012 Dec 3.
• [20] A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis.Nat Genet. 2007 Apr;39(4):523-8. doi: 10.1038/ng1976. Epub 2007 Feb 25.
• [21] Pneumococcal infection of respiratory cells exposed to welding fumes; Role of oxidative stress and HIF-1 alpha.PLoS One. 2017 Mar 9;12(3):e0173569. doi: 10.1371/journal.pone.0173569. eCollection 2017.
• [22] The role of mannose-binding lectin in pneumococcal infection.Eur Respir J. 2013 Jan;41(1):131-9. doi: 10.1183/09031936.00174111. Epub 2012 Apr 20.
• [23] Collectin Kidney 1 Plays an Important Role in Innate Immunity against Streptococcus pneumoniae Infection.J Innate Immun. 2017;9(2):217-228. doi: 10.1159/000453316. Epub 2017 Jan 10.
• [24] Interleukin-22 (IL-22) Binding Protein Constrains IL-22 Activity, Host Defense, and Oxidative Phosphorylation Genes during Pneumococcal Pneumonia.Infect Immun. 2019 Oct 18;87(11):e00550-19. doi: 10.1128/IAI.00550-19. Print 2019 Nov.
• [25] HIV gp120 in the Lungs of Antiretroviral Therapy-treated Individuals Impairs Alveolar Macrophage Responses to Pneumococci.Am J Respir Crit Care Med. 2018 Jun 15;197(12):1604-1615. doi: 10.1164/rccm.201708-1755OC.
• [26] TaqMan real time RT-PCR assays for detecting ferret innate and adaptive immune responses.J Virol Methods. 2014 Sep 1;205:38-52. doi: 10.1016/j.jviromet.2014.04.014. Epub 2014 May 4.
• [27] An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action.Nat Med. 2014 Aug;20(8):919-26. doi: 10.1038/nm.3599. Epub 2014 Jul 27.
• [28] Common NFKBIL2 polymorphisms and susceptibility to pneumococcal disease: a genetic association study.Crit Care. 2010;14(6):R227. doi: 10.1186/cc9377. Epub 2010 Dec 20.
• [29] Protective Regulatory T Cell Immune Response Induced by Intranasal Immunization With the Live-Attenuated Pneumococcal Vaccine SPY1 via the Transforming Growth Factor-1-Smad2/3 Pathway.Front Immunol. 2018 Aug 2;9:1754. doi: 10.3389/fimmu.2018.01754. eCollection 2018.
• [30] Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection.Vaccine. 2019 Jan 3;37(1):160-168. doi: 10.1016/j.vaccine.2018.11.015. Epub 2018 Nov 13.
• [31] NFKBIZ polymorphisms and susceptibility to pneumococcal disease in European and African populations.Genes Immun. 2010 Jun;11(4):319-25. doi: 10.1038/gene.2009.76. Epub 2009 Oct 1.